Magenta sets up Dianthus merger in quick, three-month about-face after ending trial due to patient death

Kyle LaHucik

Senior Reporter

Magenta Therapeutics will give its spot on Nasdaq to privately-held Dianthus Therapeutics after a patient death spurred an end to Magenta’s clinical work and an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Magenta sets up Dianthus merger in quick, three-month about-face after ending trial due to patient death

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ma­gen­ta sets up Di­anthus merg­er in quick, three-month about-face af­ter end­ing tri­al due to pa­tient death

Senior Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Magenta sets up Dianthus merger in quick, three-month about-face after ending trial due to patient death